Is TB-500 Legal in Wisconsin? Federal Framework, Prescription Rules, and How to Get It

Print or save as PDF

See the public record for TB-500

  • FDA approval / None; no approved drug contains TB-500 [1]
  • FDA bulk lists / Not on FDA's lists for state-licensed pharmacies and physicians or outsourcing facilities [2][3][4]
  • Advisory committee / Voted 23 July 2026 to recommend adding it to the pharmacy bulks list [7][5]
  • HHS draft policy / Covers TB-500 acetate injection; filed 28 October 2026 [5][6]
  • Human safety data / No exposure, toxicity or immunogenicity data found [1]
  • Sport / Prohibited at all times under WADA S2.3 [8]

What TB-500 is

TB-500 is a synthetic, N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, not the full-length protein. FDA found several salts and derivatives, including different active moieties, sold under the same name [1].

FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].

Why no compounding list covers it

FDA says a state-licensed pharmacy or physician may compound with a bulk substance only if it meets an applicable USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulk list [4]. TB-500 fits none of the three. It has no monograph, is not a component of an approved drug, and appears on neither FDA's list for state-licensed pharmacies and physicians nor the separate list for outsourcing facilities [1][2][3][4].

TB-500 does appear in the 'nominated but withdrawn' table on FDA's safety-risk page, which holds substances previously in category 2 whose nominators withdrew them. Removal from category 2 was not a finding that it is safe [9].

Questions worth asking

Choose the questions you want to keep

The committee vote and the HHS draft

On 23 July 2026 the Pharmacy Compounding Advisory Committee voted in favour of adding TB-500 to the pharmacy bulks list, against FDA staff's recommendation. TB-500 is not on the list, and adding it takes formal rulemaking [7][5].

HHS filed a draft enforcement-discretion policy on 28 October 2026 naming TB-500 among six peptides and covering TB-500 acetate given by subcutaneous or intramuscular injection. Under it, HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' [5][6]

The notice says the draft 'does not establish any rights for any person and is not binding on HHS or the public', and HHS may revisit it if a safety signal or product quality issue arises [5]. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [5].

Safety and sport

FDA found no human pharmacokinetic data for TB-500 by any route, no nonclinical toxicity studies and no immunogenicity data; its stated concern for injectable TB-500 is immunogenicity [1]. Its adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and FDA found no published case reports. Safety in humans is unknown [1].

WADA lists 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, prohibited at all times, on the 2026 and 2027 Prohibited Lists [8][10].

Is TB-500 FDA-approved?
No. FDA's July 2026 review found no approved drug containing TB-500, no USP or National Formulary monograph for it, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, or authorized by the European Medicines Agency [1].
Can a compounding pharmacy make TB-500?
TB-500 is not on FDA's bulk list for state-licensed pharmacies and physicians, nor on the list for outsourcing facilities [2][3][4]. HHS's October 2026 draft policy says it does not intend to take enforcement action against certain compounders of TB-500 acetate injection if its conditions are met [5][6].
Did an FDA advisory committee approve TB-500?
No. The Pharmacy Compounding Advisory Committee voted on 23 July 2026 to recommend adding TB-500 to the pharmacy bulks list, against FDA staff's recommendation. TB-500 is not on the list [7][5].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid thymosin beta-4 protein [1]. FDA found no article in which TB-500 itself was given to a human, so studies of full-length thymosin beta-4 do not show that TB-500 works or is safe [1].
Is TB-500 banned in sport?
WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3, prohibited at all times in and out of competition, and it appears on both the 2026 and 2027 Prohibited Lists [8][10].
Show all 10 referencesHide references
Evidence overview for Is TB-500 Legal in Wisconsin? Federal Framework, Prescription Rules, and How to Get It